Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
Status:
Enrolling by invitation
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send
additional branches to the incorrect muscles in addition to the intended muscle. This leads
to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid
Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial
muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis
causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal
periocular spasms. This study aims to evaluate an FDA approved medication for acquired
blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.